Group 1 - A total of 101 stocks in the Shanghai and Shenzhen markets have seen net inflows of main funds for five consecutive days or more as of January 21 [1] - Hangzhou Bank has the longest streak of 15 days of net inflows, ranking first, while Yunnan Baiyao follows with 13 days [1] - Demingli has the highest total net inflow amount, with 1.55 billion yuan over six days, followed closely by Hangzhou Bank with 1.44 billion yuan over 15 days [1] Group 2 - The stock with the highest proportion of net inflow relative to trading volume is Fenglong Co., which has increased by 317.94% over the past 15 days [1] - The top stocks with net inflows include Midea Group with 1.155 billion yuan over six days and Guotai Junan Securities with 1.02 billion yuan over ten days [1] - Other notable stocks with significant net inflows include Beijing Junzheng, Top Group, and China Ping An, with respective inflows of 1.006 billion yuan, 0.961 billion yuan, and 0.938 billion yuan over five days [1][2]

特此公告。 关于延长广发证券股份有限公司 2026 年面向专业投资者公开发行短期公司债券（第一期） 簿记建档时间的公告 广发证券股份有限公司（以下简称"发行人"）面向专业机构投资者公开发 行面值余额不超过 300 亿元（含）的短期公司债券已获得中国证券监督管理委员 会证监许可〔2025〕818 号文同意注册。 根据《广发证券股份有限公司 2026 年面向专业投资者公开发行短期公司债 券（第一期）发行公告》，发行人及簿记管理人原定于 2026 年 1 月 21 日 15:00-18:00 以簿记建档的方式向网下专业机构投资者进行利率询价，并根据簿记建档结果确 定本期债券的最终票面利率。 考虑到簿记建档当日市场情况，经发行人、簿记管理人及其他簿记参与方协 商一致，现将簿记建档结束时间由 2026 年 1 月 21 日 18:00 延长至 2026 年 1 月 21 日 19:00。 （以下无正文） 1 （本页无正文，为《关于延长广发证券股份有限公司 2026 年面向专业投资者公 开发行短期公司债券（第一期）簿记建档时间的公告》之盖章页） 华泰联合证券有限责任公司 年 月 日 3 （本页无正文，为《关于延长广发证券 ...

Core Viewpoint - The domestic new drug sector is entering a new growth cycle, highlighting the global value realization of Chinese innovative drugs [1] Group 1: Market Trends - By 2025, the number and scale of License out transactions are expected to reach record highs, demonstrating the global competitiveness of domestic new drugs [1] - The successful advancement of overseas clinical trials is crucial for realizing global value, indicating that business development (BD) is just the starting point [1] Group 2: Industry Participation - Several domestic new drugs are becoming flagship products for multinational corporations (MNCs), showcasing the deep involvement of Chinese pharmaceutical companies in the global medical ecosystem [1] - There is potential for a group of Chinese innovative pharmaceutical companies to grow with a global perspective and international operational capabilities [1]

Core Viewpoint - The report from GF Securities highlights that the biotechnology, new energy vehicles, and next-generation information technology sectors are currently leading in terms of industry prosperity, with these three sectors consistently ranking in the top three since October 2025 [1] Industry Summaries Biotechnology - The biotechnology sector is experiencing a turning point driven by innovation, with the past five years seeing major Chinese biotechnology companies filing 52.2% of total patent applications and 63.8% of total patent grants in history [1] New Energy Vehicles - The new energy vehicle sector is benefiting from both domestic sales and exports, with the China Passenger Car Association noting that the export performance of Chinese new energy vehicles has exceeded expectations. The growth in exports is primarily driven by plug-in hybrid and hybrid vehicles replacing pure electric vehicles as new growth points [1] Next-Generation Information Technology - The high prosperity in the next-generation information technology sector is attributed to the accelerated construction of AI computing power and extensive exploration of AI applications across various industries [1] High-End Equipment Manufacturing, New Materials, and Energy Conservation - The high-end equipment manufacturing, new materials, and energy conservation sectors are experiencing weaker prosperity, remaining in the contraction zone for three consecutive months [1]

Core Viewpoint - Guangfa Securities has received approval from the China Securities Regulatory Commission (CSRC) to issue perpetual subordinated bonds totaling up to 20 billion yuan, indicating a strategic move to strengthen its capital structure and financial flexibility [1][4]. Group 1: Trading Information - On January 20, 2026, Guangfa Securities closed at 22.77 yuan, up 1.52%, with a turnover rate of 1.0%, trading volume of 588,800 shares, and a transaction value of 1.337 billion yuan [1]. - On the same day, the net outflow of funds from major investors was 5.7121 million yuan, while retail investors saw a net inflow of 36.5784 million yuan [4]. Group 2: Company Announcements - Guangfa Securities has been approved to publicly issue perpetual subordinated bonds with a total face value not exceeding 20 billion yuan, with the approval valid for 24 months from the date of registration [1][4]. - The company plans to issue its first phase of short-term corporate bonds in 2026, with a scale not exceeding 3 billion yuan, a term of 365 days, and the proceeds intended for repaying maturing short-term corporate bonds [1][2][4]. - The short-term bonds will be issued only to professional institutional investors, with a credit rating of A-1 and a stable outlook, reflecting the company's strong competitive position and financial service capabilities [2].

Core Viewpoint - The article highlights the increasing trend of securities firms in China to sell insurance products, driven by regulatory support and the need for wealth management transformation amid operational pressures [1][5][18]. Group 1: Regulatory Changes and Market Trends - Starting from 2025, the China Securities Association (CSRC) aims to promote more compliant securities firms to obtain licenses for selling bank wealth management and insurance products [1]. - The presence of insurance products on the shelves of securities firms has been steadily increasing, indicating a shift towards insurance sales [4][6]. - Major securities firms like CITIC Securities, China Merchants Securities, and Ping An Securities have launched insurance sections on their apps, showcasing a variety of insurance products alongside traditional financial offerings [3][10]. Group 2: Sales Pressure and Employee Experiences - Employees at leading securities firms are experiencing significant pressure to meet insurance sales targets, leading to a growing emphasis on insurance sales in their daily work [2][22]. - The performance metrics for insurance sales have become a focal point, with employees often feeling overwhelmed during peak sales periods [2][22]. Group 3: Product Offerings and Market Position - As of now, the number of securities firms holding insurance intermediary licenses remains unchanged from 2022, with only 11 firms licensed to sell insurance [6]. - Despite the limited number of licensed firms, major players are actively expanding their insurance product offerings, with Ping An Securities offering 56 products and CITIC Securities offering 20 [8][10]. - The insurance products being sold are primarily focused on life insurance and annuities, reflecting a trend towards financial products with investment attributes rather than pure risk coverage [10][19]. Group 4: Competitive Landscape and Challenges - The competitive landscape for insurance sales is evolving, with securities firms leveraging their existing client bases and expertise in asset management to penetrate the insurance market [20][22]. - However, the dominance of banks in the insurance distribution channel remains a significant challenge for securities firms, as banks have extensive networks and established customer relationships [22]. - Regulatory scrutiny is increasing, with upcoming regulations aimed at ensuring appropriate management of cross-industry sales, which may pose additional challenges for securities firms [24].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 GF SECURITIES CO., LTD. 廣發証券股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1776） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，廣發証券股份有限公司（「本公司」）在深圳 證券交易所網站( http://www.szse.cn )刊發的《廣發証券股份有限公司2026年面向專 業投資者公開發行短期公司債券（第一期）發行公告》。茲載列如下，僅供參閱。 承董事會命 廣發証券股份有限公司 林傳輝 董事長 中國，廣州 2026年1月20日 於本公告日期，本公司董事會成員包括執行董事林傳輝先生、秦力先生、孫曉燕 女士及肖雪生先生；非執行董事李秀林先生、尚書志先生及郭敬誼先生；獨立非 執行董事梁碩玲女士、黎文靖先生、張闖先生及王大樹先生。 广发证券股份有限公司2026年面向专业投资者公开 发行 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 GF SECURITIES CO., LTD. 廣發証券股份有限公司 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，廣發証券股份有限公司（「本公司」）在深圳 證券交易所網站( http://www.szse.cn )刊發的《廣發証券股份有限公司2026年面向專 業投資者公開發行短期公司債券（第一期）信用評級報告》。茲載列如下，僅供參 閱。 承董事會命 廣發証券股份有限公司 林傳輝 董事長 中國，廣州 2026年1月20日 於本公告日期，本公司董事會成員包括執行董事林傳輝先生、秦力先生、孫曉燕 女士及肖雪生先生；非執行董事李秀林先生、尚書志先生及郭敬誼先生；獨立非 執行董事梁碩玲女士、黎文靖先生、張闖先生及王大樹先生。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1776） 海外監管公告 广发证券股份有限公司 2026 年面向专业投资者 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 GF SECURITIES CO., LTD. 廣發証券股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1776） 根據中華人民共和國的有關法例規定，廣發証券股份有限公司（「本公司」）在深圳 證券交易所網站( http://www.szse.cn )刊發的《廣發証券股份有限公司2026年面向專 業投資者公開發行短期公司債券（第一期）募集說明書》。茲載列如下，僅供參閱。 承董事會命 廣發証券股份有限公司 林傳輝 董事長 中國，廣州 2026年1月20日 於本公告日期，本公司董事會成員包括執行董事林傳輝先生、秦力先生、孫曉燕 女士及肖雪生先生；非執行董事李秀林先生、尚書志先生及郭敬誼先生；獨立非 執行董事梁碩玲女士、黎文靖先生、張闖先生及王大樹先生。 （住所：广东省广州市黄埔区中新广州知识城腾飞一街 2 ...

广发证券股份有限公司2026年面向专业投资者公开 牵头主承销商/债券受托管理人 （住所：深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小镇 B7 栋 401） 联席主承销商/簿记管理人 （深圳市福田区福田街道益田路 5023 号平安金融中心 B 座第 22-25 层） 签署日期： 年 月 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 发行短期公司债券（第一期） 发行公告 发行人 （住所：广东省广州市黄埔区中新广州知识城腾飞一街 2 号 618 室） 重要事项提示 1、广发证券股份有限公司（以下简称"发行人"或"公司"）已于 2025 年 4 月 16 日获得中国证券监督管理委员会"证监许可〔2025〕818 号"文获批可面向专业投资者公 开发行面值余额不超过 300 亿元（含）的短期公司债券（以下简称"本次债券"）。 2、本期债券简称为"26 广发 D1"，债券代码为"524639"。本期债券每张面值为 100 元，发行数量不超过 3,000 万张（含），发行价格为人民币 100 元/张。本期债券发 行总规模为不超过 30 亿元（含）。 3 ...